commentary

May 08 FX Commentary: Boris Schlossberg

Boris Schlossberg, BK Asset Management




commentary

May 08 Equities Commentary: Todd Colvin

Todd Colvin, Ambrosino Brothers




commentary

May 08 Energy Commentary: Todd Colvin

Todd Colvin, Ambrosino Brothers




commentary

May 08 Livestock Commentary: Virginia McGathey

Virginia McGathey, www.VirginiaMcGathey.com




commentary

May 08 Grains Commentary: Virginia McGathey

Virginia McGathey, www.VirginiaMcGathey.com




commentary

May 08 Metals Commentary: Dan Deming

Dan Deming, KKM Financial




commentary

May 08 Bonds Commentary: Dan Deming

Dan Deming, KKM Financial




commentary

MAY 09 FX Commentary: Bob Iaccino

Bob Iaccino, Path Trading Partners




commentary

May 09 Energy Commentary: Bob Iaccino

Bob Iaccino, Path Trading Partners




commentary

MAY 09 GRAINS COMMENTARY: Scott Shellady

Scott Shellady, TJM Investments




commentary

May 09 Livestock Commentary: Scott Shellady

Scott Shellady, TJM Investments




commentary

May 09 Equities Commentary: Scott Bauer

Scott Bauer, Prosper Trading Academy




commentary

May 09 Bonds Commentary: Dan Deming

Dan Deming, KKM Financial




commentary

May 09 Metals Commentary: Bob Iaccino

Bob Iaccino, Path Trading Partners




commentary

May 10 AM London FX Commentary: Eddie Tofpik

Eddie Tofpik, Adm Investor Services International Limited




commentary

May 10 Grains Commentary: Virginia McGathey

Virginia McGathey, www.VirginiaMcGathey.com




commentary

May 10 Livestock Commentary: Virginia McGathey

Virginia McGathey, www.VirginiaMcGathey.com




commentary

May 10 Equities Commentary: Larry Shover

Larry Shover, Efficient Advisors




commentary

May 10 Metals Commentary: Larry Shover

Larry Shover, Efficient Advisors




commentary

May 10 Bonds Commentary: Todd Colvin

Todd Colvin, Ambrosino Brothers




commentary

May 10 FX Commentary: Bob Iaccino

Bob Iaccino, Path Trading Partners




commentary

May 10 Energy Commentary: Bob Iaccino

Bob Iaccino, Path Trading Partners




commentary

May 13 Grains Commentary: Virginia McGathey

Virginia McGathey, www.VirginiaMcGathey.com




commentary

May 13 Livestock Commentary: Virginia McGathey

Virginia McGathey, www.VirginiaMcGathey.com




commentary

May 13 Metals Commentary: Todd Colvin

Todd Colvin, Ambrosino Brothers




commentary

May 13 Energy Commentary: Dan Deming

Dan Deming, KKM Financial




commentary

May 13 FX Commentary: Bob Iaccino

Bob Iaccino, Path Trading Partners




commentary

May 13 Equities Commentary: Bob Iaccino

Bob Iaccino, Path Trading Partners




commentary

Plitidepsin: a Repurposed Drug for the Treatment of COVID-19 [Commentary]

Finding antivirals to reduce coronavirus disease 2019 (COVID-19) morbidity and mortality has been challenging. Large randomized clinical trials that aimed to test four repurposed drugs, hydroxychloroquine, lopinavir-ritonavir, interferon beta 1a, and remdesivir, have shown that these compounds lack an impact on the COVID-19 course. Although the phase III COVID-19 vaccine trial results are encouraging, the search for effective COVID-19 therapeutics should not stop. Recently, plitidepsin (aplidin) demonstrated highly effective preclinical activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Its antiviral activity was 27.5-fold more potent than that of remdesivir (K. M. White, R. Rosales, S. Yildiz, T. Kehrer, et al., Science, 2021, https://science.sciencemag.org/content/early/2021/01/22/science.abf4058). Plitidepsin, a repurposed drug developed for the treatment of multiple myeloma, targets the host translation cofactor eEF1A. Plitidepsin has shown efficacy in animal models and phase I/II human trials. Although plitidepsin is administered intravenously and its toxicity profile remains to be fully characterized, this compound may be a promising alternative COVID-19 therapeutic.




commentary

God’s Own Commentary on the Cross (Matthew 27:45-53)

Check here each week to keep up with the latest from John MacArthur's pulpit at Grace Community Church.




commentary

Editor’s Commentary




commentary

The National Center for Complementary and Integrative Health: Priorities for Cannabis and Cannabinoid Research [Special Section: Cannabinoid Signaling in Human Health and Disease-Commentary]

The National Center for Complementary and Integrative Health (NCCIH), which is part of the US National Institutes of Health (NIH), has a broad interest in studying the biologic activities of natural products, especially those for which compelling evidence from preclinical research suggests biologic activities that may be beneficial to health or have a potential role in disease treatment, as well as products used extensively by the American public. As of 2023, use of cannabis for medical purposes is legal in 38 states and Washington, D.C. Such use continues to climb generally without sufficient knowledge regarding risks and benefits. In keeping with NCCIH’s natural product research priorities and recognizing this gap in knowledge, NCCIH formally launched a research program in 2019 to expand research on the possible benefits for pain management of certain substances found in cannabis: minor cannabinoids and terpenes. This Viewpoint provides additional details and the rationale for this research priority at NCCIH. In addition, NCCIH’s efforts and initiatives to facilitate and coordinate an NIH research agenda focused on cannabis and cannabinoid research are described.

SIGNIFICANCE STATEMENT

Use of cannabis for purported medical purposes continues to increase despite insufficient knowledge regarding risks and benefits. Research is needed to help health professionals and patients make knowledgeable decisions about using cannabis and cannabinoids for medical purposes. The National Center for Complementary and Integrative Health, along with other NIH Institutes, Centers, and Offices, is expanding study on the safety, efficacy, and harms of cannabis—a complex mixture of phytochemicals that needs to be studied alone and in combination.




commentary

Cannabis and Cannabinoid Signaling: Research Gaps and Opportunities [Special Section: Cannabinoid Signaling in Human Health and Disease-Commentary]

Cannabis and its products have been used for centuries for both medicinal and recreational purposes. The recent widespread legalization of cannabis has vastly expanded its use in the United States across all demographics except for adolescents. Meanwhile, decades of research have advanced our knowledge of cannabis pharmacology and particularly of the endocannabinoid system with which the components of cannabis interact. This research has revealed multiple targets and approaches for manipulating the system for therapeutic use and to ameliorate cannabis toxicity or cannabis use disorder. Research has also led to new questions that underscore the potential risks of its widespread use, particularly the enduring consequences of exposure during critical windows of brain development or for consumption of large daily doses of cannabis with high content 9-tetrahydrocannabinol. This article highlights current neuroscience research on cannabis that has shed light on therapeutic opportunities and potential adverse consequences of misuse and points to gaps in knowledge that can guide future research.

SIGNIFICANCE STATEMENT

Cannabis use has escalated with its increased availability. Here, the authors highlight the challenges of cannabis research and the gaps in our knowledge of cannabis pharmacology and of the endocannabinoid system that it targets. Future research that addresses these gaps is needed so that the endocannabinoid system can be leveraged for safe and effective use.




commentary

The treatise on the divine nature [Electronic book] : Summa theologiae I, 1-13 / Thomas Aquinas ; translated, with commentary, by Brian Shanley ; introduction by Robert Pasnau.

Indianapolis : Hackett Publishing Company, Inc., [2006]




commentary

Popol vuh : the Mayan book of the dawn of life [Electronic book] / translated by Dennis Tedlock ; with commentary based upon the ancient knowledge of the modern Quiché Maya.

[Place of publication not identified] : [eBookIt.com], [1996]




commentary

The intimate life of an Ottoman statesman [Electronic book] : Melek Ahmed Pasha (1588-1662) : as portrayed in Evliya Çelebi's Book of travels (Seyahat-name) / translation and commentary by Robert Dankoff ; with a historical introduction by Rhoads

Albany : State University of New York Press, [1991]




commentary

African Ecological Ethics and Spirituality for Cosmic Flourishing : An African Commentary on Laudato Si' [Electronic book] / Stan Chu Ilo, Agbonkhianmeghe E. Orobator.

Eugene, Oregon : Wipf and Stock, 2022.




commentary

Barbora Krejcikova slams analyst for ‘unprofessional commentary’ about her looks




commentary

Snogworthy jams + social commentary

Once while eating dinner in Montreal, our friendly, intoxicated waitress plopped herself in my lap and proceeded to tell us about how obsessed she was with the CD that was playing - singing out the lyrics at an ungodly volume and flinging her arms about. Wow, I thought to myself, people who listen to Morcheeba sure seem to have a lot of fun, and promised to check them out.

Several CDs later, they are firmly one of my favorites. And their trip hop meditation, 2003’s Charango remains one of my most played CDs.

Morcheeba (Mor = more, Cheeba = pot) are brothers Ross and Paul Godfrey with singer Skye Edwards (who has since been replaced). Part trance, part ambience, Charango is full of smooth, snogworthy jams. And just as you surrender to its seductive groove, Slick Rick shows up with a rap called “Women Lose Weight”.

Lamenting his wife putting on weight after having kids and stalled by his mistress who wants a clean break before she shacks up with him, he decides the easiest way out of it all is to kill the spouse. Considering different ways to do the deed, he finally rams his car into her Chevy over a long lunch break one fine day. It is an unexpected, stunning, tongue-in-cheek social commentary that makes it a CD you won’t forget easily.

Rave Out © 2007 IndiaUncut.com. All rights reserved.
India Uncut * The IU Blog * Rave Out * Extrowords * Workoutable * Linkastic





commentary

‘Felt sick’: Commentary legend spills on feud with Eddie McGuire

Aussie sports commentator Tim Lane has revealed he “felt sick” in the moment he realised his employer had double crossed him on the eve of the AFL season.




commentary

A Skills Beyond School Commentary on Canada

This commentary is one of a series of country reports on postsecondary vocational education and training (VET) in OECD countries, prepared as part of an OECD study. The series includes reviews, involving an in-depth analysis of a country system leading to a set of policy recommendations backed by analysis.




commentary

Philanthropist and Filmmaker Hits a Goldmine of Talents for his Social Commentary Productions

Ramu Gorai utilizes both local American and Indian talent in his movies to address a variety of social issues.




commentary

Philanthropist and Filmmaker Searches Talents for Social Commentary Productions

Ramu Gorai encourages both local American and Indian talent in his production, which deal with a variety of social issues. Production appreciates the Star Indian American Model Prakash Patil for his extraordinary talent and contribution to the fashio




commentary

Philanthropist and Filmmaker Searches Talents for Social Commentary Productions

Ramu Gorai encourages both local American and Indian talent in his production, which deal with a variety of social issues. Production appreciates the Star Indian American Model Prakash Patil for his extraordinary talent and contribution to the fashion and entertainment arena.




commentary

Commentary: Racing Has A New Set Of Wagering Customers, But Now What?

Some of you might have read the USA Today Network story about horse racing this week. The piece highlighted some pretty impressive statistics related to the broadcast and marketing of the limited racing calendar we've all been experiencing. One quote caught my eye: “NYRA chief revenue officer Tony Allevato said it had signed up seven […]

The post Commentary: Racing Has A New Set Of Wagering Customers, But Now What? appeared first on Horse Racing News | Paulick Report.




commentary

Josh Spiegel Commentary: A Ravens Poem

Josh Spiegel shares a special poem for Ravens fans who are still dealing with the loss to the Titans.




commentary

Josh Spiegel Commentary: The Coronavirus Blame Game

Josh Spiegel talks about the Coronavirus and unleashes a torrent of blame on China and its eating habits.




commentary

Josh Spiegel Commentary: The State Of Our Union

While Democrats and Republicans have been divided for years, Josh Spiegel says, during the State of the Union speech, it was clear there's bipartisan support for despising each other.




commentary

Josh Spiegel Commentary: The Final Word On The Pugh Scandal

In a week that saw the release of former Baltimore Mayor Catherine Pugh's apology video and Pugh being sentenced to federal prison for conspiracy and tax evasion, Josh Spiegel offers his wrap up on the Healthy Holly saga.